| Sally Bodensteiner, MD | |
|
406 N 1st St, Vincennes, IN 47591-1340 | |
| (812) 882-1106 | |
| (812) 885-2758 |
| Full Name | Sally Bodensteiner |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 19 Years |
| Location | 406 N 1st St, Vincennes, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851580823 | NPI | - | NPPES |
| 01074304A | Other | IN | INDIANA LICENSE |
| 201260890 | Medicaid | IN | |
| 000000898810 | Other | IN | ANTHEM |
| 258190 | Other | IN | MEDICARE GROUP |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 01074304A (Indiana) | Primary |
| 208D00000X | General Practice | MD2008-0602 (New Mexico) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Good Samaritan Home Care Services Of Vincennes In | Vincennes, IN | Home health agency |
| Good Samaritan Hospital | Vincennes, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Good Samaritan Hospital Physician Services Inc | 3971671330 | 129 |
| Good Samaritan Family Health Center Inc | 5294099321 | 12 |
News Archive
Merck today provided an update on the development programs for vorapaxar, extended release niacin/laropirprant (MK524A, Tredaptive) and anacetrapib in association with the European Society of Cardiology (ESC) meeting in Munich.
Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months.
Results from the landmark RE-COVER(TM) study were presented today at the American Society of Hematology Annual Meeting and published online in the New England Journal of Medicine.
Actavis Group has announced that it has launched Ondansetron Tablets in the U.S. Actavis will market the product under an agreement with Natco Pharma Limited. Distribution of the product will commence immediately.
› Verified 1 days ago
| Entity Name | Deaconess Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427097443 PECOS PAC ID: 9032021431 Enrollment ID: O20040115000129 |
News Archive
Merck today provided an update on the development programs for vorapaxar, extended release niacin/laropirprant (MK524A, Tredaptive) and anacetrapib in association with the European Society of Cardiology (ESC) meeting in Munich.
Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months.
Results from the landmark RE-COVER(TM) study were presented today at the American Society of Hematology Annual Meeting and published online in the New England Journal of Medicine.
Actavis Group has announced that it has launched Ondansetron Tablets in the U.S. Actavis will market the product under an agreement with Natco Pharma Limited. Distribution of the product will commence immediately.
› Verified 1 days ago
| Entity Name | Apogee Medical Group Indiana Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093973885 PECOS PAC ID: 8729155742 Enrollment ID: O20080917000320 |
News Archive
Merck today provided an update on the development programs for vorapaxar, extended release niacin/laropirprant (MK524A, Tredaptive) and anacetrapib in association with the European Society of Cardiology (ESC) meeting in Munich.
Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months.
Results from the landmark RE-COVER(TM) study were presented today at the American Society of Hematology Annual Meeting and published online in the New England Journal of Medicine.
Actavis Group has announced that it has launched Ondansetron Tablets in the U.S. Actavis will market the product under an agreement with Natco Pharma Limited. Distribution of the product will commence immediately.
› Verified 1 days ago
| Entity Name | Good Samaritan Hospital Physician Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649432071 PECOS PAC ID: 3971671330 Enrollment ID: O20081013000182 |
News Archive
Merck today provided an update on the development programs for vorapaxar, extended release niacin/laropirprant (MK524A, Tredaptive) and anacetrapib in association with the European Society of Cardiology (ESC) meeting in Munich.
Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months.
Results from the landmark RE-COVER(TM) study were presented today at the American Society of Hematology Annual Meeting and published online in the New England Journal of Medicine.
Actavis Group has announced that it has launched Ondansetron Tablets in the U.S. Actavis will market the product under an agreement with Natco Pharma Limited. Distribution of the product will commence immediately.
› Verified 1 days ago
| Entity Name | Good Samaritan Family Health Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174031256 PECOS PAC ID: 5294099321 Enrollment ID: O20190219002426 |
News Archive
Merck today provided an update on the development programs for vorapaxar, extended release niacin/laropirprant (MK524A, Tredaptive) and anacetrapib in association with the European Society of Cardiology (ESC) meeting in Munich.
Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months.
Results from the landmark RE-COVER(TM) study were presented today at the American Society of Hematology Annual Meeting and published online in the New England Journal of Medicine.
Actavis Group has announced that it has launched Ondansetron Tablets in the U.S. Actavis will market the product under an agreement with Natco Pharma Limited. Distribution of the product will commence immediately.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sally Bodensteiner, MD 406 N 1st St, Vincennes, IN 47591-1340 Ph: (812) 882-1106 | Sally Bodensteiner, MD 406 N 1st St, Vincennes, IN 47591-1340 Ph: (812) 882-1106 |
News Archive
Merck today provided an update on the development programs for vorapaxar, extended release niacin/laropirprant (MK524A, Tredaptive) and anacetrapib in association with the European Society of Cardiology (ESC) meeting in Munich.
Chronic myelomonocytic leukemia (CMML) is a rare type of myelodysplastic, myeloproliferative neoplasm characterized by increased numbers of peripheral monocytes and less than 20 percent blasts. CMML has few treatment options and patients only survive on average for 12 to 24 months.
Results from the landmark RE-COVER(TM) study were presented today at the American Society of Hematology Annual Meeting and published online in the New England Journal of Medicine.
Actavis Group has announced that it has launched Ondansetron Tablets in the U.S. Actavis will market the product under an agreement with Natco Pharma Limited. Distribution of the product will commence immediately.
› Verified 1 days ago
Dr. Michelle Lee Snyder, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 328 N 2nd St Ste 102, Vincennes, IN 47591 Phone: 812-910-0544 Fax: 812-494-2600 | |
Daniel J Herman Jr., M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 406 N 1st St, Vincennes, IN 47591 Phone: 812-885-0524 Fax: 812-885-0523 | |
Scott R Keyes, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 520 S 7th St, Vincennes, IN 47591 Phone: 812-885-3810 | |
Dr. Heather Michele Ludwig Akers, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 406 N 1st St, Vincennes, IN 47591 Phone: 812-882-1106 Fax: 812-885-2758 | |
Scott A Stine, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 406 N 1st St, Vincennes, IN 47591 Phone: 812-882-1106 Fax: 812-895-2458 | |
Kristin A Mahan, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 406 N 1st St, Vincennes, IN 47591 Phone: 812-882-1106 Fax: 812-895-2458 | |
Jane M. Bridges, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 Willow St, Suite 200, Vincennes, IN 47591 Phone: 812-885-8040 Fax: 812-885-8043 |